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Intravenous amiodarone was approved in 1995 for the treat-
ment of malignant and resistant ventricular arrhythmia. Al-
though it is an “old drug,” much has been learned recently about
this complex drug and its application in a variety of cardiac
arrhythmias. The objectives of this review were to summarize what
is known about intravenous amiodarone, including its pharmaco-
logic and electrophysiologic effects, to review its efficacy for the
treatment of patients with highly malignant ventricular arrhyth-
mia and to provide specific information about its clinical use for
this and other indications. The studies that were reviewed were
selected on the basis of time published (from 1983 to 1995) and
the completeness of information provided regarding patient clin-
ical characteristics, drug dosing and methods of evaluation,
efficacy analyses, long-term follow-up and complications. The full
data from the three controlled trials that formed the basis of the
drug’s approval are contained in published reports that were also
extensively reviewed. Intravenous amiodarone has demonstrable
efficacy for the treatment of frequently recurrent destabilizing
ventricular tachycardia and ventricular fibrillation, with suppres-
sion rates of 63% to 91% in uncontrolled trials. The three pivotal
trials confirmed these findings and demonstrated a dose–response
relation, with at least comparable efficacy to bretylium, a drug
with a similar indication. The safety profile has also been well
described; cardiovascular adverse effects are the most frequent,
especially hypotension. Intravenous amiodarone is a useful addi-
tion to the drugs available for the treatment of patients with very
severe ventricular arrhythmia. Its use in patients with other
rhythm disorders appears promising, but final recommendations
must await development of definitive data from ongoing clinical
trials.
(J Am Coll Cardiol 1997;29:1190–8)
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Amiodarone has emerged as an important drug for the treat-
ment of cardiac arrhythmia (1,2). Its clinical use is increasing
as evidence mounts as to its utility for a variety of forms of
atrial and ventricular arrhythmias. It can be anticipated that
indications for its use may broaden in the next few years as
several key clinical trials conclude (3,4). For example, the
European Myocardial Infarct Amiodarone Trial (EMIAT) and
the Canadian Amiodarone Myocardial Infarction Arrhythmia
Trial (CAMIAT) have been completed and the preliminary
results presented (5,6). It would appear that amiodarone has
the potential to reduce arrhythmic mortality in patients after
myocardial infarction, even though there was no difference in
overall survival.
Intravenous amiodarone, like the oral form, has been
available in several countries for many years (7,8). It was
originally used in the United States under licenses obtained by
individual investigators (9). When a U.S. firm obtained mar-
keting rights in the mid-1980s, individual licenses were re-
voked, and the company began controlled clinical trials that
were completed in 1992. The data from those trials were
presented to the Food and Drug Administration in 1994, and
the drug was approved in August 1995 for the acute suppres-
sion of hemodynamically destabilizing ventricular tachycardia
(VT) and ventricular fibrillation (VF) refractory to therapy
with conventional antiarrhythmic drugs. The purpose of this
report is to review intravenous amiodarone, including its
pharmacology, efficacy and safety data, dosing recommenda-
tions and other relevant information, to provide a framework
for its proper clinical use.
Pharmacology
Pharmacokinetics. As with the oral form, intravenous ami-
odarone has a complex pharmacology that begins with its
formulation (10). Because it is not water soluble, the commer-
cial preparation uses a solvent—polysorbate-80—that may
contribute to the hypotensive effect of the commercially avail-
able compound (11). Polysorbate-80 has also been shown to
decrease heart rate, depress atrioventricular (AV) node con-
duction and increase atrial and ventricular refractory periods
(12). Once infused, a large percentage of amiodarone is
protein bound predominantly to albumin and also to beta-
lipoprotein and alpha-1 acid glycoprotein, an acute-phase
reactant (13,14). The drug is metabolized mainly by a P450
cytochrome oxidase (CYP3A4)-dependent oxidative deethyla-
tion. The principal metabolite is desethylamiodarone, which is
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active and has an electrophysiologic effect similar to the parent
compound (15). Many other metabolic pathways are known to
exist, including glucuronidation, which precedes biliary clear-
ance. A much smaller amount of metabolite is produced when
the drug is given intravenously rather than orally unless the
drug is infused for several days (16). Amiodarone is widely
distributed in the body after intravenous administration, and a
three-compartment model best explains its distribution kinet-
ics (17). In addition to a relatively small central compartment,
there appears to be both a peripheral and deep compartment.
Highest levels of amiodarone and its primary metabolite have
been found in the deep compartment, which consists of lymph
nodes, liver, lung, and fat and has a steady state partition
coefficient relative to plasma of 100 to 1,000 (15). The periph-
eral compartment is composed of muscle and brain that
provide a smaller volume of distribution and a lower solubility
coefficient. This model helps to explain the observed phases of
plasma elimination after drug discontinuation, including a
fairly short initial half-life followed by a much longer elimina-
tion period as amiodarone redistributes from deep stores (18).
The longer the infusion of intravenous amiodarone, the
greater the amount of parent and metabolite that is deposited
in the deep compartment. The presence of a large, deep site of
distribution accounts for the delay in the onset of antiarrhyth-
mic activity when smaller loading doses are used; a higher dose
is necessary to attain a myocardial and plasma concentration
during the time that the deep compartment is being filled (19).
Elimination is through the biliary system, with essentially no
renal component, so that doses need not be adjusted in renal
failure (20,21). Amiodarone cannot be removed with dialysis
(22). With the possible exception of massive hepatic failure,
systemic diseases, including congestive heart failure, do not
mandate intravenous amiodarone dose reduction, nor is there
any need to use lower doses in the elderly (23).
Drug interactions. Intravenous amiodarone, like the oral
form, would be expected to interact with a large number of
other drugs, either pharmacokinetically or pharmacodynami-
cally, especially when used for several days (24). Amiodarone
inhibits the action of subtypes of the cytochrome P-450 enzyme
system. It will increase the levels of several drugs that are thus
metabolized, including quinidine, procainamide and warfarin
(25,26). The mechanism of the interaction between amioda-
rone and digoxin is complex, but amiodarone may double
steady state digoxin plasma levels when administered concom-
itantly (27). In addition, drugs such as barbiturates should
decrease, and cimetidine may increase, serum amiodarone
concentrations. Perhaps more relevant to the use of the
intravenous formulation is the pharmacodynamic interactions
between amiodarone and a variety of drugs that slow the sinus
node and retard conduction through the AV node, including
beta-adrenergic and calcium channel blocking agents as well as
digitalis (28,29). This is particularly relevant in the treatment
of patients with underlying conduction system disease.
Electrophysiologic actions. Intravenous amiodarone has a
number of electrophysiologic actions by virtue of its diverse
effects on specialized and nonspecialized atrial and ventricular
tissue (30,31). It slows intraventricular conduction by blocking
the sodium channel; slows the heart rate and impedes AV
node conduction by blocking beta-adrenergic receptors and
calcium channels; and prolongs atrial and ventricular repolar-
ization by inhibiting potassium channels (32). Sodium channel
block probably results from interaction with a number of
channel conformations (33,34). The net effect is slowing of
conduction that is frequency dependent (exaggerated at higher
heart rates). Nanas and Mason (35) have reported a significant
correlation between conduction velocity slowing and canine
ventricular myocardial concentrations during intracoronary
infusion. This early electrophysiologic effect was not accompa-
nied by changes in repolarization. The antisympathetic effect is
caused by a noncompetitive alpha- and beta-blockade (36).
Although this effect may not be detected by a decrease in heart
rate, it may be an important factor in the suppression of acute
electrical instability. Depression of sinus rhythm and AV node
function in the early phases of treatment is a net result of
variable contributions of beta-adrenergic and calcium channel
blockade, either or both of which suppress triggered activity
and thus may explain the low proarrhythmia potential of
amiodarone (37). It may also be that these early electrophysi-
ologic effects may be the most important factor in distinguish-
ing the intravenous from the oral form of the drug. The class
III action of the drug may be the least identifiable during the
early phases of intravenous therapy. Right ventricular effective
refractory periods, prolongation of which is an index of class
III effect, are minimally increased during the early phases of
intravenous dosing (38,39). A potassium channel blocking
action may be more relevant and important during long-term
therapy (40). The effects of intravenous amiodarone on pacing
and defibrillation thresholds have not been well studied, but a
clinically significant increase in defibrillation threshold in
animal models or humans has not been shown (41,42).
Hemodynamic effects. The predominant hemodynamic ef-
fect of intravenous amiodarone is hypotension caused by a
combination of arterial vasodilation and negative inotropy
(43). The former may be caused in part by its solvent
polysorbate-80 (11). Blood pressure decreases commonly, even
in patients without preexisting left ventricular dysfunction, but
hypotension may be ameliorated by slowing the rate of infu-
sion. The direct negative inotropic effect of the drug is minimal
and transient, may be partially caused by its antisympathetic
effect and usually does not lead to a decreased cardiac output.
The net hemodynamic effect in patients with antecedent left
Abbreviations and Acronyms
AV 5 atrioventricular
CAMIAT 5 Canadian Amiodarone Myocardial Infarction Arrhythmia
Trial
CHF 5 congestive heart failure
EMIAT 5 European Myocardial Infarct Amiodarone Trial
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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ventricular dysfunction is of particular importance because
these patients are the usual treatment targets. This has been
addressed in small trials in which such patients have been
studied and have had no significant change in hemodynamic
profile and no deterioration in functional status (44). Individ-
ual cases of hemodynamic collapse have been reported in this
impaired population, especially when the drug is infused
rapidly (45).
Efficacy
There have been numerous observational studies regarding
the efficacy of amiodarone for VT and VF (Table 1) (46–54).
There is so much diversity among these studies in terms of
patient populations, drug doses and methods of evaluation that
it is difficult to derive any firm conclusions about efficacy. Most
of these trials included patients in whom previous attempts to
control VT or VF, or both, with available drugs had failed.
Nevertheless, these studies have value because they indicate
that intravenous amiodarone can reduce the frequency of
recurrence of VT and VF and can terminate ventricular
arrhythmias in very ill patients, including some undergoing
resuscitation at the time they received the drug. The studies
also provide some guidance as to selection of an effective drug
dose and have identified potential adverse effects that helped
in designing proper clinical trials.
Three large clinical trials of the relative safety and efficacy
of intravenous amiodarone were initiated in the late 1980s and
were completed and published within the past year (55–57)
(Table 2). The enrollment criterion for all three studies was at
least two episodes of hemodynamically destabilizing VT or VF
within 24 h of entry despite treatment with lidocaine, procain-
amide and bretylium (except in the bretylium comparison
study). The index arrhythmias were not associated with QT
prolongation and were not caused by a drug or electrolyte
abnormality. The patient population was similar in the three
studies. The average age was 60 years, with a male preponder-
ance. Most of the patients had coronary artery disease and
acute or old myocardial infarction. The mean left ventricular
ejection fraction was 30%. Approximately 25% of patients
were on a ventilator or intraaortic balloon pump before
enrollment; 11% were having an acute myocardial infarction;
10% were undergoing cardiopulmonary resuscitation; and
.20% could not give informed consent because of altered
consciousness.
Because placebo-controlled studies were not deemed fea-
sible and were probably unethical in such ill patients, alterna-
tive designs were sought. The first was a randomized, double-
blind, dose-ranging study in which a clear difference in
response rates among the three dose groups could be consid-
ered a surrogate for efficacy (55). This study used doses of 500,
1,000 and 2,000 mg/24 h. Dosing started with 75 to 300 mg
administered over 10 min, followed by an infusion of 0.5, 1.0 or
2.0 mg/min for 6 h and then a maintenance infusion of 0.25, 0.5
or 1.0 mg/min for the next 24 h. Differences in event rates and
time to first event did not reach statistical significance. Adverse
effects occurred with about equal frequency among the three
dose groups. Total and cardiac mortality rates were not
different among the groups.
The second trial was also a dose-ranging study but used a
lower range of doses of 125, 500 and 1,000 mg/day (56). As in
the other trials, ;90% of the patients enrolled had VT, and the
remaining 10% had VF. There were more events per hour and
a shorter time to first event in the low dose group, and the
outcome differences among groups were of borderline statis-
tical significance. In addition, provisions had been made in the
protocol for supplemental boluses of 150 mg of intravenous
amiodarone for recurrent arrhythmias. The number of supple-
mental doses per hour of study was significantly greater in the
patients assigned to the 125-mg dose than in those in the
Table 1. Selected Clinical Trials
Study (ref no.) Arrhythmia
No. of
Pts
Daily Dose
Acute
Efficacy
(% of pts)
Adverse Effects
(% of pts)
Follow-Up
Initial
Infusion
(24 h)
Mean
Time
Survival
Rate
Morady et al. (46) VT 15 5 mg/kg 600–1,000 mg 80% AV block (7%) 8 mo 92%
Klein et al. (47) VT 13 5 mg/kg 10 mg/kg 69% Shock (8%) N/A N/A
Helmy et al. (48) VT/VF 46 5 mg/kg 1,000 mg 72% Hypotension/shock (13%) 24 mo 54%
Schmidt et al. (49) VT/VF 36 300 mg 900–1,200 mg 81% Hypotension (20%) 10 mo 62%
Ochi et al. (50) VT/VF 22 240–480 mg 900–1,600 mg 64% CHF (9%) 22 mo 36%
Schutzenberger et al. (51) VT/VF 26 5 mg/kg 1,050 mg 73% Hypotension (19%),
bradycardia (4%),
proarrhythmia (4%)
N/A N/A
Williams et al. (52) CA 14 150–600 mg N/A 79% CHF (14%),
bradycardia (14%)
14 mo 21%
Mooss et al. (53) VT/VF 35 5 mg/kg 20–30 mg/kg 63% Hypotension (23%),
bradycardia (14%)
19 mo 34%
Nalos et al. (54) VT 22 300 mg 1,440 mg 91% Hypotension (41%),
bradycardia (23%)
N/A 86%
AV 5 atrioventricular; CA 5 cardiac arrest; CHF 5 congestive heart failure; N/A 5 not applicable; Pts 5 patients; ref 5 reference; VF 5 ventricular fibrillation;
VT 5 ventricular tachycardia.
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1,000-mg dose group (0.21 vs. 0.11, p , 0.04), a finding that
was a confirmation of dose responsiveness.
The third major efficacy study was a double-blind compar-
ison with bretylium, a drug previously approved for similar
indications (58,59). Patients were randomized to receive treat-
ment with conventional doses of bretylium and either 125 or
1,000 mg of intravenous amiodarone (57). The higher dose of
amiodarone and bretylium had comparable response rates
(using the same end points) in this trial, and patients receiving
either of those treatments fared better than those in the low
dose amiodarone group (Table 2). The intention to treat
analysis was partially confounded by a high rate of crossover
from bretylium to open label amiodarone, primarily because of
intolerable hypotension that occurred about twice as often with
bretylium as with high dose amiodarone. Once again, there was
no mortality difference among the three therapies. A post hoc
analysis of all three controlled trials was carried out to
determine whether there were any clinical characteristics in
this patient population that could predict a favorable response
both in terms of event and mortality rates (60). Patients with
preserved left ventricular function (ejection fraction .35%)
who received a dose of 1,000 mg/24 h had a median of 1.0
events/48 h compared with 3.8 events/48 h in patients with an
ejection fraction ,35%. The difference in mortality between
these groups was also statistically significant.
Safety
Observational studies of intravenous amiodarone have pro-
vided some data regarding its potential short- and long-term
toxicity. Unfortunately, none of these trials were large enough
or of sufficient duration to permit definitive conclusions (46–
54,61–64). The three large clinical trials were useful because
the data were carefully collected and catalogued; some patients
received the drug for several weeks; and follow-up information
was immediately available. In addition, when the controlled
trials were concluded, investigators were permitted to enroll
patients in an open label trial. At last analysis, 1,836 patients
were in this data set (65). Interpretation of this large body of
information is confounded by the fact that there was no
placebo group in any of the trials. Thus, in this sick patient
population, it is not possible to discern which adverse effects
are due to drug or to the underlying disease process.
Cardiovascular adverse effects were most common, and the
most frequent of these was hypotension, occurring in 10% to
30% of patients in the controlled trials. It was observed more
commonly with rapid rates of infusion, but in the clinical trials
there was no significant difference in the incidence of hypo-
tension among the dose groups. Less than 10% of the patients
who developed hypotension in the controlled trials had blinded
therapy discontinued. The majority responded to adjustment
of the rate of infusion, fluid administration or judicious use of
a parenteral vasopressor or inotrope. Severe bradycardia and
second- and third-degree AV block, both intranode and infra-
node, have also been reported and were seen in the clinical
trials with a frequency of ,2% (66,67). However, 10% to 20%
of patients who developed this complication required a tem-
porary transvenous pacemaker for rate support if the drug was
continued. Although intravenous amiodarone causes QT pro-
longation, the incidence of torsade de pointes was low (,1%)
(37,68). However, identifying worsening arrhythmia in a pa-
tient population with such frequent episodes is difficult. The
prospective definition of ventricular proarrhythmia for all the
clinical trials was torsade de pointes (long QT interval and
polymorphous VT initiated with a typical short–long–short
cycle length) or the development of VF after drug infusion in
patients who only had VT before the drug. Approximately
1.3% of patients in these trials had arrhythmia aggravation
using these criteria (65).
Noncardiac adverse effects have been reported frequently
both in published reports and in the clinical trial experience
(69). Many of these were nonspecific and possibly related to
the underlying disease process. A variety of pulmonary, he-
patic, endocrine and cutaneous complications were reported in
the clinical trials, but none appeared to have the typical
features of the organ toxicity reported during long-term oral
Table 2. Results From Three Pivotal Trials
Study (ref no.)
Dose
Groups
(mg/24 h)
Presenting
Arrhythmia
No. of
Events/
24 h
Pts
Event
Free at
24 h
(%)
Mean No. of
Supplemental
Boluses/h
Mortality
Rate at
48 h (%)
Cardiovascular Adverse Event Rate (%)
VT IVT VF Hypotension Bradycardia Asystole Proarrhythmia CHF
Levine et al. (55) 500 60 22 6 N/A 30 0.24 20 17 6 6 5 1
1,000 56 32 4 N/A 40 0.18 21 10 3 3 1 2
2,000 61 27 5 N/A 38 0.15 22 17 6 4 1 2
Scheinman et al. (56) 125 68 37 12 1.68 37 0.21 21 24 5 5 0 3
500 62 43 14 0.96 42 0.14 19 27 7 7 2 2
1,000 64 29 13 0.48 43 0.11 22 26 5 5 1 4
Kowey et al. (57) 125 71 21 7 1.68 38 0.16 13 24 2* — 1 0
1,000 64 25 11 0.48 43 0.16 12 27 3 — 0 0
2,500 71 18 11 0.96 46 0.22 17 26 4 — 1 5
(bretylium)
*Reported as heart block/node rhythm. IVT 5 incessant ventricular tachycardia, other abbreviations as in Table 1.
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therapy, and they frequently resolved despite continuation of
the drug. Organ toxic side effects, such as transaminase
elevation and thyroid abnormalities, did increase in frequency
in the patients who were treated with the intravenous prepa-
ration for a longer period of time. This observation supports
the notion that the duration of therapy is an important factor
in the emergence of certain noncardiac adverse effects.
Clinical issues
Dosing. On the basis of the pharmacologic profile of
intravenous amiodarone, there appears to be a large interin-
dividual variation in time to response during the initiation of
intravenous therapy (70). Consequently, dosing recommenda-
tions derived from the clinical trial experience provide a
guideline only. Close patient observation and dose adjustments
are essential. For example, hypotension and other cardiac
adverse effects that may be seen during initial rapid infusion
may improve substantially with a decrease in the rate of
infusion. In contrast, supplemental boluses are frequently
needed for patients who have recurrent arrhythmias during the
early phases of dosing. The recommended initial loading dose
is 150 mg administered over 10 min, followed by an interme-
diate infusion of 1 mg/min for 6 h and then 0.5 mg/min
thereafter. Supplemental boluses of 150 mg may be given over
10 to 30 min for recurrent arrhythmias, but because hypoten-
sion occurs more frequently at daily doses .2,000 mg/day, no
more than six to eight supplemental boluses in any 24-h period
may be possible. Plasma levels are not routinely used because
they are high and uninterpretable in the early phases of
therapy and because there is a wide variation in “effective
concentrations” of parent and metabolite (16,19,71). In clinical
trials with the oral preparation, there has been only a rough
correlation between dose and serum level and no correlation
between serum level and efficacy or toxicity (56,57). Serum
levels of the metabolite are very low in patients dosed for only
a few days.
When given intravenously, amiodarone should be mixed in
a 5% dextrose solution and should be infused with a volumetric
pump. If used in high concentrations (.2 mg/ml), it must be
delivered through a central vein because it can cause periph-
eral phlebitis in ,3% of patients. It has been stated that the
drug should be placed in glass bottles because it absorbs
polyvinyl chloride and that adhesion in plastic tubing is pre-
vented by flow, but those recommendations have been chal-
lenged (72,73). Amiodarone does not need light protection but
is physically incompatible with a number of drugs such as
heparin with which it is frequently used. Although it was
thought that amiodarone was physically incompatible with
normal saline, Campbell et al. (73) showed that this is a
satisfactory admixture.
In the multicenter trials, the median duration of intrave-
nous amiodarone therapy was 4 days, but there was wide
variation. Patients who could not take oral medication were
treated for .3 to 6 weeks without difficulty. Over 95% of
patients in the controlled trials went on to receive oral therapy.
The bioavailability of oral versus intravenous amiodarone has
varied from 30% to 70% in assorted studies (10,15). Bioavail-
ability also appears to be lower in elderly patients and those
with cardiopulmonary disease (74). Recommendations regard-
ing the transition to oral therapy take into account these
properties in addition to the fact that there may be a delay of
4 to 5 h between ingestion of the oral drug and an increase in
the plasma level. Generally, the longer the patient has been
receiving intravenous therapy, the less the need for the cus-
tomary large oral loading doses.
Transition to oral therapy and follow-up testing. Over
90% of the patients who received intravenous amiodarone in
controlled clinical trials went on to receive oral therapy. This
conversion rate was high because the patients had severe
arrhythmias that were not due to an easily reversible cause
(75). When the drug is used in clinical situations in which the
underlying condition can be remedied, such as in patients with
acute myocardial infarction and successful revascularization,
the rate of conversion to oral therapy will probably diminish.
Patients who have been receiving intravenous therapy for .2
to 3 weeks can be started safely on maintenance doses of oral
amiodarone (300 to 400 mg/day). Those treated for ,1 week
should probably receive the usual oral loading regimen of 800
to 1,400 mg/day, whereas an intermediate dose of 400 to
800 mg/day might be suitable for patients who fall in between
these time frames. If there is any concern about gastrointesti-
nal function, oral and intravenous therapy should both be
maintained for a few days. These recommendations are em-
piric, based on the usual target total drug dose for in-hospital
loading and are not based on careful pharmacologic trials.
A situation may arise in which a patient who is receiving
long-term therapy temporarily cannot take oral medication.
Because amiodarone is slowly eliminated, cessation of therapy
for a few days is probably of little consequence, but patients
should have electrocardiographic monitoring within 5 to 7 days
because of the drug’s biphasic elimination profile. If oral
therapy cannot be started after that time, and if there is doubt
about adequate gastrointestinal absorption, intravenous ther-
apy can be substituted. A loading dose is not necessary; based
on the known range of its bioavailability, infusion of 30% to
70% of the patient’s daily oral dose will suffice.
Intravenous amiodarone has been used for treatment of
patients who have received long-term oral therapy and have
had recurrent arrhythmias. Under these circumstances, it
should be assumed that the patient has insufficient myocardial
tissue concentrations, especially if the QT interval is not
prolonged (76). It is customary in these situations to use the
recommended loading and maintenance doses of the intrave-
nous formulation until the arrhythmia is suppressed and then
to prescribe oral therapy, as previously described.
After a patient has received loading doses of either the oral
or intravenous preparation, the question may arise as to the
need for an evaluation to confirm clinical efficacy before
patient discharge because suppression of arrhythmia with an
intravenous antiarrhythmic drug does not necessarily predict
efficacy of its oral formulation. Furthermore, the sporadic
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nature of recurrent VT/VF often makes short-term suppres-
sion of clinical arrhythmia difficult to interpret. The options are
either to monitor the patient to determine whether repetitive
forms, especially nonsustained VT, have been suppressed or to
carry out electrophysiologic testing. Although proof of ambient
arrhythmia suppression is frequently obtained before dis-
charge, there are no definitive data to prove the value of either
method. Two small studies that have attempted to examine the
role of predischarge electrophysiologic testing arrived at con-
tradictory conclusions (77,78). It is our custom to perform
electrophysiologic testing and to consider implantation of an
arrhythmia control device in those cases in which the arrhyth-
mia can be induced and causes hemodynamic instability de-
spite treatment with intravenous and then oral amiodarone.
Such testing is generally done after the patient is clinically
stable and has received the equivalent of 6 to 10 g of oral
amiodarone, a dose that has been shown to produce a variable
but reasonable plasma concentration and to suppress sponta-
neous ventricular ectopic beats (10,15,79).
Other indications. Most of the information available about
intravenous amiodarone relates to ventricular arrhythmias.
Because it has some effect on atrial myocardium, the sinus and
AV nodes and accessory pathways, some investigators have
explored the efficacy of the drug for supraventricular indica-
tions (31,80–82). In patients with accessory pathway-related
tachycardias, including AV reentry tachycardia and antero-
grade conduction during atrial fibrillation/flutter, the drug may
slow conduction or terminate the arrhythmia (38). It may work
synergistically with other negatively dromotropic drugs to slow
the ventricular response rate during atrial arrhythmias. How-
ever, the rate of conversion of atrial fibrillation or flutter to
normal sinus rhythm within 24 h of administration is lower
than that reported with class Ic or even some other class III
agents (83,84). Nevertheless, because of its safety in patients
with poor left ventricular function and the relatively low
incidence of ventricular proarrhythmia, it is occasionally used
in the urgent treatment of atrial fibrillation with rapid conduc-
tion that causes hemodynamic embarrassment (85–87). In a
recently reported study, Galve et al. (88) confirmed that
patients treated with intravenous amiodarone whose rhythm
did not convert to sinus rhythm had a significantly slower heart
rate response than those treated with digoxin alone. The
reported experience with the drug in patients after coronary
artery bypass graft surgery is similar (83,85,87–89). It is less
effective than class Ic drugs for conversion but is useful for rate
control and may prevent recurrence of atrial fibrillation in
those with electrical conversion to sinus rhythm after drug
loading. Intravenous amiodarone may prevent postoperative
atrial fibrillation when given prophylactically either before or
immediately after operation, but this question requires more
detailed investigation (90).
There are no data to support the use of intravenous
amiodarone for primary prophylaxis against ventricular ar-
rhythmias in any clinical situation. Likewise, there have been
no studies that have directly compared the efficacy of the oral
and intravenous preparations for the suppression of VT or VF.
One recent study by Russo et al. (91) found that doses of 1,200
to 1,400 mg/day of the oral form might be beneficial in a cohort
that was similar to the patients in the clinical trials (91). Nine
of the 12 patients entered into that study survived to hospital
discharge. Because that study was uncontrolled and had a
small number of patients, adequate conclusions about the role
of oral therapy are not possible. However, because of the
vagaries of bioavailability, oral loading in patients with highly
malignant arrhythmia should be implemented with caution.
Although time to effect may be shortened by administration
of intravenous rather than oral amiodarone, giving clinically
stable patients loading doses of the intravenous formulation
provides little potential benefit. The total daily dose that can be
delivered safely may be higher with the oral formulation
because hypotension is usually not seen, even with oral doses
of up to 3 g/day (gastrointestinal side effects at these doses are
more common) (92). In addition, the cost of the intravenous
formulation should be a consideration in this strategy. Not only
does the drug itself cost more, but its administration obligates
extended observation periods in an intensive care setting, with
a higher level of nursing care than that required for oral
loading. The concept of combining oral and intravenous doses
to truncate the loading period has not been studied adequately.
Special patient groups. There is some reported experience
with intravenous amiodarone in infants, children and adoles-
cents (93,94). A recent study from Figa et al. (95) and earlier
smaller published reports have indicated that the drug, when
used in proportionate per kilogram doses, has efficacy similar
to that reported for adults. The principal adverse effect was
symptomatic bradycardia requiring a temporary pacemaker in
a small percentage of children. Recently, Perry et al. (96)
published the results of a small multicenter protocol in which
intravenous amiodarone was administered to critically ill pe-
diatric patients. They concluded that the intravenous form is
safe and effective in young patients with critical tachycardias,
including supraventricular arrhythmias.
Intravenous amiodarone is toxic to embryos in selected
animal species (97). In humans, amiodarone and desethylami-
odarone cross the placenta and reach levels in the fetus of up
to 50% of maternal serum levels (98). The principal toxicity
that has been seen in such fetuses has been hyperthyroidism,
hypothyroidism and congenital goiter (99). A recent report by
Ovadia et al. (100) described one major and two minor
congenital anomalies in which amiodarone was administered
throughout the embryonic period. Amiodarone has no effect
on the duration of gestation or labor in rats, but inadequate
data are available in humans. Amiodarone and desethylamio-
darone have been found in breast milk in humans, and nursing
offspring of rats fed amiodarone have reduced body weight
gain and life expectancy (101). For all these reasons, pregnant
woman should receive the drug only if other options have been
exhausted. Breastfeeding is contraindicated for women taking
amiodarone.
Guidelines for clinical use. How might intravenous amio-
darone fit into an algorithm for the treatment of patients with
recurrent, hemodynamically destabilizing VT or VF? Intrave-
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nous lidocaine should and will remain first-line therapy for this
patient group. Although it has a low efficacy rate, it is very
familiar to practitioners and is relatively safe when used in
proper doses (102). Its short half-life after rapid loading makes
interactions with successive drugs less likely. For patients who
do not respond to lidocaine, procainamide is frequently cho-
sen. The evidence of procainamide’s efficacy comes mainly
from studies in which it was used to terminate or prevent the
reinduction of monomorphic VT (103). Bretylium is generally
considered a third-line drug primarily because of its tendency
to cause severe hypotension (104,105). Data from the recent
clinical trials provide reassurance that bretylium is beneficial in
this clinical situation, although hypotension occurs frequently
and can be sustained over several days (57). Intravenous
beta-blockers should also be considered on the basis of results
of small series in which such agents have been effective (106).
Their principal liability is myocardial depression, which is a
particularly important problem in this patient population.
According to the controlled clinical trials, intravenous
amiodarone can be considered effective therapy for patients in
whom conventional therapy fails. Although a myocardial de-
pressant, intravenous amiodarone does not appear to cause
congestive heart failure as frequently as intravenous beta-
blockers, possibly because of its vasodilator properties. For
patients who continue to have frequent arrhythmias despite
the use of supplemental boluses of intravenous amiodarone,
other parenteral agents may be added. Although there is scant
experience with parenteral antiarrhythmic drug combinations,
procainamide, quinidine and propafenone have been added to
oral amiodarone with evidence of supplemental efficacy
(107,108). The mortality rate for patients with incessant ven-
tricular arrhythmias that do not respond to such aggressive
pharmacologic therapy is high despite emergent surgical or
catheter ablation (109,110).
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